Chelsea’s Northera Clears FDA But With A Confirmatory Trial Requirement
This article was originally published in The Pink Sheet Daily
Northera was approved by FDA under the Subpart H accelerated approval pathway; the Indications and Usage section of the drug’s labeling notes the lack of efficacy data for treatment with the drug beyond two weeks.
You may also be interested in...
The Greatest US FDA Advisory Committees: A Look Back At Tumult And Turning Points
With two landmark advisory committee meetings coming up, the Pink Sheet reflects on some of the most memorable panel meetings over the last 20 years.
Accelerated Approval: Midodrine Experience Shows Regulatory Challenge US FDA Faces With Makena
The orthostatic hypotension treatment midodrine has been on the market for more than 20 years despite the failure of postmarketing studies to confirm clinical benefit; an advisory committee soon will weigh the future of AMAG’s preterm birth drug Makena, which failed its confirmatory trial required as a condition of accelerated approval.
Durability Questions Mean Northera Should Be Limited To Short-Term Use, Panel Says
The durability of treatment effect for Chelsea’s NOH drug is an issue for a post-marketing study to answer, FDA’s Cardiovascular and Renal Drugs Advisory Committee said in recommending approval on a 16-1 vote.